Literature DB >> 18272218

C3435T polymorphism of the MDR1 gene is not associated with P-glycoprotein function of leukemic blasts and clinical outcome in patients with acute myeloid leukemia.

Eun-Hye Hur1, Je-Hwan Lee, Michael Jinpyo Lee, Seong-Jun Choi, Jung-Hee Lee, Mun Jung Kang, Miee Seol, Yae Eun Jang, Hee-Jung Lee, Ip-Sol Kang, Soo-Kyung Shim, Seong-Gil Ryu, Young-Ah Kang, Young-Shin Lee, Chan-Jeoung Park, Hyun-Sook Chi, Kyoo-Hyung Lee.   

Abstract

We investigated the association between the MDR1 C3435T polymorphism and P-glycoprotein function of leukemic blasts as well as clinical outcomes in 200 patients with AML, excluding the M3 subtype. The CC, CT and TT genotype frequencies of the C3435T polymorphism among patients were 71, 93 and 36, respectively. The C3435T polymorphism genotypes did not have influence on the P-glycoprotein function of leukemic blasts. Complete remission rates and overall, relapse-free and event-free survival rates were not significantly different among the C3435T polymorphism genotypes. In conclusion, the MDR1 C3435T polymorphism does not appear to have significant clinical implications in AML.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18272218     DOI： 10.1016/j.leukres.2007.12.013

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


  7 in total

Review 1.  Positive impact of ABCB1 polymorphisms in overall survival and complete remission in acute myeloid leukemia: a systematic review and meta-analysis.

Authors:  J E Megías-Vericat; L Rojas; M J Herrero; V Bosó; P Montesinos; F Moscardó; J L Poveda; M A Sanz; S F Aliño
Journal:  Pharmacogenomics J       Date:  2015-10-27       Impact factor: 3.550

2.  Association of ABCB1 polymorphisms with prognostic outcomes of anthracycline and cytarabine in Chinese patients with acute myeloid leukemia.

Authors:  Hui He; Jiye Yin; Xi Li; Yu Zhang; Xiaojing Xu; Ming Zhai; Juan Chen; Chenyue Qian; Honghao Zhou; Zhaoqian Liu
Journal:  Eur J Clin Pharmacol       Date:  2015-01-09       Impact factor: 2.953

Review 3.  Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature.

Authors:  Stefan Wolking; Elke Schaeffeler; Holger Lerche; Matthias Schwab; Anne T Nies
Journal:  Clin Pharmacokinet       Date:  2015-07       Impact factor: 6.447

4.  Influence of ABCB1 polymorphisms upon the effectiveness of standard treatment for acute myeloid leukemia: a systematic review and meta-analysis of observational studies.

Authors:  J E Megías-Vericat; L Rojas; M J Herrero; V Bosó; P Montesinos; F Moscardó; J L Poveda; M Á Sanz; S F Aliño
Journal:  Pharmacogenomics J       Date:  2015-01-06       Impact factor: 3.550

Review 5.  Systematic Review of Pharmacogenetics of ABC and SLC Transporter Genes in Acute Myeloid Leukemia.

Authors:  Juan Eduardo Megías-Vericat; David Martínez-Cuadrón; Antonio Solana-Altabella; José Luis Poveda; Pau Montesinos
Journal:  Pharmaceutics       Date:  2022-04-17       Impact factor: 6.525

Review 6.  Immune plexins and semaphorins: old proteins, new immune functions.

Authors:  Kelly Roney; Eda Holl; Jenny Ting
Journal:  Protein Cell       Date:  2013-01-11       Impact factor: 14.870

Review 7.  Role of Pharmacogenetics in the Treatment of Acute Myeloid Leukemia: Systematic Review and Future Perspectives.

Authors:  Álvaro Pinto-Merino; Jorge Labrador; Pablo Zubiaur; Raquel Alcaraz; María José Herrero; Pau Montesinos; Francisco Abad-Santos; Miriam Saiz-Rodríguez
Journal:  Pharmaceutics       Date:  2022-03-03       Impact factor: 6.321
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.